Holdings
AlphaCentric Life Sciences and Healthcare Fund
As of Jun 30, 2026, AlphaCentric Life Sciences and Healthcare Fund reported 59 positions worth US$44.1M. Largest: Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated and Astrazeneca Plc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 20,426 | US$2.58M | +166 | Jun 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 5,002 | US$2.48M | +71 | Jun 30, 2026 |
| Astrazeneca Plc | 11,394 | US$2.16M | +162 | Jun 30, 2026 |
| Roivant Sciences Ltd. | 48,355 | US$1.71M | +688 | Jun 30, 2026 |
| Argenx Se | 1,806 | US$1.68M | +12 | Jun 30, 2026 |
| Neurocrine Biosciences, Inc. | 9,727 | US$1.64M | +120 | Jun 30, 2026 |
| Incyte Corporation | 14,451 | US$1.64M | +206 | Jun 30, 2026 |
| Axsome Therapeutics, Inc. | 6,531 | US$1.6M | +93 | Jun 30, 2026 |
| Apogee Therapeutics, Inc. | 11,533 | US$1.53M | +164 | Jun 30, 2026 |
| Ionis Pharmaceuticals, Inc. | 15,430 | US$1.22M | −4,157 | Jun 30, 2026 |